The clinical added value of the addition of anti-CTL-4 to anti-PD-1 alone is questionable and clearly increasing toxicity regarding pivotal studies in the treatment of melanoma and renal carcinoma.

Authors :: Albin N
Monard A
Lapiere J
Source :: Cancer chemotherapy and pharmacology [Cancer Chemother Pharmacol] 2019 May; Vol. 83 (5), pp. 1003-1005. Date of Electronic Publication: 2019 Mar 04.
Publication Year :: 2019

Subjects :: Antineoplastic Agents, Immunological administration & dosage
Antineoplastic Agents, Immunological therapeutic use
Antineoplastic Combined Chemotherapy Protocols administration & dosage
Antineoplastic Combined Chemotherapy Protocols therapeutic use
Humans
Immunotherapy methods
Kidney Neoplasms metabolism
Melanoma metabolism
Antineoplastic Agents, Immunological adverse effects
Antineoplastic Combined Chemotherapy Protocols adverse effects
CTLA-4 Antigen antagonists & inhibitors
Kidney Neoplasms drug therapy
Melanoma drug therapy
Programmed Cell Death 1 Receptor antagonists & inhibitors

Full Text Access

Tools